Merger Alert: Pharmacare Ltd t/a Aspen Pharmacare and certain rights held by Ingelheim Pharmaceuticals (Pty) Ltd
The following Merger Alert is for information purposes only and is not binding on the Competition Tribunal or any member of the Tribunal
| Type of matter | Parties involved | Tribunal Decision |
| Large merger | Pharmacare Ltd t/a Aspen Pharmacare and certain rights held by Ingelheim Pharmaceuticals (Pty) Ltd | Approved with conditions |
The Competition Tribunal has approved a merger that will see Pharmacare Ltd, trading as Aspen Pharmacare (Aspen), acquire the promotion, sales, marketing and distribution rights to 17 branded pharmaceutical products held by Ingelheim Pharmaceuticals (Pty) Ltd (Ingelheim SA). The approval is subject to employment-related conditions.
The acquiring group (Aspen Holdings, Aspen and their subsidiaries) manufactures, sells and distributes generic and branded pharmaceutical drugs in South Africa. It has a global network of manufacturing and packaging facilities, with local operations in Gqeberha, Cape Town and East London.
Boehringer Ingelheim International GmbH develops, manufactures and sells pharmaceutical products. While it has no manufacturing facilities in South Africa, it supplies the local market through its wholly owned subsidiary, Ingelheim SA. It has research and development facilities as well as manufacturing facilities around the world.
Issued by:
Gillian de Gouveia, Communications Manager
On behalf of the Competition Tribunal of South Africa
Cell: +27 (0) 82 410 1195
E-Mail: GillianD@comptrib.co.za
Twitter: @comptrib
Back to Press Releases
